SERPASIL-ESIDRIX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Serpasil-esidrix, and what generic alternatives are available?
Serpasil-esidrix is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in SERPASIL-ESIDRIX is hydrochlorothiazide; reserpine. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SERPASIL-ESIDRIX?
- What are the global sales for SERPASIL-ESIDRIX?
- What is Average Wholesale Price for SERPASIL-ESIDRIX?
Summary for SERPASIL-ESIDRIX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
DailyMed Link: | SERPASIL-ESIDRIX at DailyMed |
![SERPASIL-ESIDRIX drug patent expirations Drug patent expirations by year for SERPASIL-ESIDRIX](/p/graph/s/t/SERPASIL-ESIDRIX-patent-expirations.png)
US Patents and Regulatory Information for SERPASIL-ESIDRIX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SERPASIL-ESIDRIX #1 | hydrochlorothiazide; reserpine | TABLET;ORAL | 011878-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | SERPASIL-ESIDRIX #2 | hydrochlorothiazide; reserpine | TABLET;ORAL | 011878-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |